Vice President of External Science & Innovation, Pfizer. ES&I is responsible for identifying and establishing relationships with key external partners to capitalize on complementary areas of expertise. Through these collaborations, ES&I creates unique opportunities for Pfizer researchers and partners to drive the discovery and development of potential new therapies that address areas of high unmet medical need.
Dr Itescu has served on the Mesoblast Board since the Company's founding in 2004, was Executive Director from 2007, and became CEO and Managing Director in 2011. Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, the University of Melbourne and Monash University in Australia.
In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Hear from Dr Itescu about his experience developing the largest global regenerative medicine company from an Australian start-up.
Set to play an instrumental role in advancing Australian innovation, Charlie Day is tasked with developing a strategy to build a robust and effective innovation system by 2030. Delivering a plenary presentation at AusBiotech 2017, Charlie, the Chief Executive Officer of Innovation and Science Australia (ISA), will provide an update on the Innovation, Science and Research (ISR) System and strategic plan development.
Read Charlie Day names his top challenges as CEO of Innovation and Science Australia from the Australian Financial Review.
How can supply chain development help create cures in the twenty-first century? In his plenary presentation, Tim Oldham will examine supply chains from a biotech perspective and discuss its implications for product development. Tim is the Chief Executive Officer of Cell Therapies, which is a recognised leader in manufacturing and distribution of cell-based therapies. Read more about Cell Therapies.
Peter Molloy is the CEO of Race Oncology Ltd. In addition, since 2014, he has been an Adjunct Teaching Fellow at Swinburne University of Technology, where he has given guest lectures on biotechnology strategy and commercialisation and recently published a paper on the challenges of strategic planning for biotech firms. He has also undertaken research into the performance of the Australian biotech sector from 2003-2016, focussing on drug development biotech firms. The research provides the first comprehensive, long-term, performance analysis of the Australian drug development biotech sector and in this session, he will share the results of that research, prior to their future publication. He will also address key questions such as: how ‘biotech’ firms are defined, how value creation is measured, and what the value creation drivers and impediments are for Australian firms. It promises to be an interesting and enlightening plenary session.
Dr Craig Rayner is the President of d3 Medicine and has more than 15 years of drug development experience. His past appointments include leadership roles in Clinical Pharmacology and Early development (Roche), Clinical Development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche) and as an academic researcher in clinical pharmacology and infectious disease research (Monash University).
Dr Rayner has extensive experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities. He holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), and is broadly published in clinical pharmacology and also infectious diseases.
Dr Begley was this year announced as CEO of BioCurate, an $80 million joint venture launched by Monash University and the University of Melbourne, with support from the Victorian Government.
BioCurate is an independent venture catalyst designed to specifically target the early phases of drug development and provide the commercial focus, expertise and funding needed to boost successful translation and commercialisation. BioCurate will work closely with the universities and their partners in health, research and industry.
The Millis Oration is name after Emertius Professor Nancy Millis (1922-2012), the First Lady of biotechnology.
We gratefully acknowledge our session partners: